π₯πΊπΈ#OCGN #Π²Π°ΠΊΡΠΈΠ½Π°
Ocugen ΠΏΠΎΠ΄Π°Π» Π·Π°ΡΠ²ΠΊΡ Π² FDA Π½Π° ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΡΠ²ΠΎΠ΅ΠΉ Π°Π½ΡΠΈΠΊΠΎΠ²ΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ Π΄Π»Ρ ΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π² Π‘Π¨Π Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΉ 2-18 Π»Π΅Ρ
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXINβ’ (BBV152) for Children Ages 2-18 Years
Ocugen ΠΏΠΎΠ΄Π°Π» Π·Π°ΡΠ²ΠΊΡ Π² FDA Π½Π° ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΡΠ²ΠΎΠ΅ΠΉ Π°Π½ΡΠΈΠΊΠΎΠ²ΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ Π΄Π»Ρ ΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π² Π‘Π¨Π Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΉ 2-18 Π»Π΅Ρ
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXINβ’ (BBV152) for Children Ages 2-18 Years